

SUPPLEMENTARY **EUROPEAN SEARCH REPORT**

Application Number EP 01 92 2785

		RED TO BE RELEVANT	Delevier	OL ACCIDIOATION OF THE		
Category	Citation of document with inc of relevant passa		Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.CI.7)		
P,X	of lymph node metast colorectal cancer" ANTICANCER RESEARCH.	/ 2000 (2000-05), pages 541	1-20, 34-38	C12Q1/68		
X	WILTZ 0 ET AL: "EXF ENZYMATICALLY ACTIVE A UBIQUITOUS PROPER ADENOCARCINOMAS" GASTROENTEROLOGY, vol. 100, no. 5 PAR 1266-1278, XP0080469 ISSN: 0016-5085	E SUCRASE ISOMALTASE IS TY OF COLON T 1, 1991, pages	1-20,33			
Υ		the whole document * 34-38				
X	LISE M ET AL: "Asso sucrase-isomaltase colorectal cancer." ANNALS OF SURGICAL JOURNAL OF THE SOCI ONCOLOGY. MAR 1997, vol. 4, no. 2, Marc 176-183, XP00804655. ISSN: 1068-9265 * the whole document	21,24	TECHNICAL FIELDS SEARCHED (Int.CI.7)			
X	ZWEIBAUM A ET AL: MARKER OF FETAL AND CELLS OF THE HUMAN INTERNATIONAL JOURN vol. 32, no. 4, 198 XP008046567 ISSN: 0020-7136 * the whole documen The supplementary search reposet of claims valid and available	AL OF CANCER, 3, pages 407–412, t *	21,24			
	Place of search	Date of completion of the search	1	Examiner		
	Munich	29 July 2005	He	lliot, B		
X:pa Y:pa do A:teo O:no	CATEGORY OF CITED DOCUMENTS inticularly relevant if taken alone inticularly relevant if combined with anot current of the same category chnological background on-written disclosure termediate document	E : earlier patent do after the filing da	ocument, but pu te in the application for other reasor	blished on, or on IS		



SUPPLEMENTARY **EUROPEAN SEARCH REPORT**

Application Number EP 01 92 2785

Category	Citation of document with income of relevant passa		Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.CI.7)
Х	JESSUP J M ET AL: 'an independent progr colorectal carcinoma DISEASES OF THE COLO	'Sucrase-isomaltase is nostic marker for a." DN AND RECTUM. DEC cember 1995 (1995-12), 008046582	21,24	
Х	the Cdx1 and Cdx2 ho	5–29), pages 38465	1	TECHNICAL FIELDS
X	MALLO G V ET AL: "I SEQUENCING AND EXPR ENCODING HUMAN CDX1 DOWN-REGULATION OF EXPRESSION DURING CO CARCINOGENESIS" INTERNATIONAL JOURN NY, US, vol. 74, no. 1, 20 February 1997 (1: 35-44, XP000946393 ISSN: 0020-7136 * page 37, paragrap * abstract *	ESSION OF THE MRNA AND CDX2 HOMEOBOX. CDX1 AND CDX2 MRNA OLORECTAL AL OF CANCER, NEW YORK, 997-02-20), pages	1,2, 9-12,19 20	SEARCHED (Int.CI.7)
	The supplementary search reposet of claims valid and available		Evenior	
	Place of search	Date of completion of the search	u^	Examiner 11iot, B
	Munich	29 July 2005		
X:pa Y:pa do: A:ted O:no	CATEGORY OF CITED DOCUMENTS rticularly relevant if taken alone rticularly relevant if combined with anot cument of the same category chnological background in-written disclosure ermediate document	E : earlier patent do after the filling do her D : document cited L : document cited	ocument, but pui ate in the application for other reason	blished on, or on S



SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application Number EP 01 92 2785

Citation of document with in of relevant passa		1		1 /1-4 (01.70)
	iges	to clair	n APPLICATION	1 (Int.Cl.7)
US 5 518 888 A (WALI 21 May 1996 (1996-09 * abstract *		34-38		
24 March 1998 (1998-	-03-24)	1-20, 33-38		
11 February 1997 (19	997-02-11)	1-20, 33-38		
requirements for CDX2 binding to the cis promoter element mediating intestine-specific expression of guanylyl cyclase C" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS,		cis nylyl		
Place of search Munich ATEGORY OF CITED DOCUMENTS ticularly relevant if taken alone ticularly relevant if combined with anounent of the same category	Date of completion of to 29 July 20 T: theo E: earli after D: doc: L: docu	no search 105 Try or principle underlying the repatent document, but the filing date urment cited in the appliument cited for other reasons.	g the invention t published on, or cation asons	
	US 5 731 159 A (WALI 24 March 1998 (1998- * the whole document US 5 601 990 A (WALI 11 February 1997 (19 * the whole document DI GUGLIELMO 1 M D I requirements for CD promoter element med intestine—specific ocyclase C" FEBS LETTERS, ELSEV AMSTERDAM, NL, vol. 507, no. 2, 26 October 2001 (20128-132, XP00431203 ISSN: 0014-5793 * the whole document Place of search Munich ATEGORY OF CITED DOCUMENTS icularly relevant if taken alone icularly relevant if taken alone icularly relevant if combined with another icularly relevant if combined w	US 5 731 159 A (WALDMAN ET AL) 24 March 1998 (1998–03–24) * the whole document * US 5 601 990 A (WALDMAN ET AL) 11 February 1997 (1997–02–11) * the whole document * DI GUGLIELMO 1 M D ET AL: "Nucleotic requirements for CDX2 binding to the promoter element mediating intestine—specific expression of guar cyclase C" FEBS LETTERS, ELSEVIER SCIENCE PUBLIAMSTERDAM, NL, vol. 507, no. 2, 26 October 2001 (2001–10–26), pages 128–132, XP004312033 ISSN: 0014–5793 * the whole document * The supplementary search report has been based on the lass set of claims valid and available at the start of the search. Place of search Munich Place of search Munich ATEGORY OF CITED DOCUMENTS T: theo E: earlicularly relevant if taken alone with another unrel of the same category unnological background everytien disclosure E: earlicularly relevant if taken alone with another unrel of the same category unnological background everytien disclosure E: earlicularly relevant if taken alone with another unrel of the same category unnological background everytien disclosure E: earlicularly relevant if taken alone with another unrel of the same category unnological background everytien disclosure E: earlicularly relevant if taken alone with another unrel of the same category unnological background everytien disclosure E: earlicularly relevant if taken alone with another unrel of the same category unnological background everytien disclosure E: earlicularly relevant if taken alone with another unrel of the same category unrelevant if taken alone with another unrel of the same category unrelevant if taken alone with another unrel of the same category unrelevant if taken alone with another unrel of the same category unrelevant if taken alone with another unrelevant if take	US 5 731 159 A (WALDMAN ET AL) 24 March 1998 (1998–03–24) * the whole document * US 5 601 990 A (WALDMAN ET AL) 11 February 1997 (1997–02–11) * the whole document * DI GUGLIELMO 1 M D ET AL: "Nucleotide requirements for CDX2 binding to the cis promoter element mediating intestine–specific expression of guanylyl cyclase C" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 507, no. 2, 26 October 2001 (2001–10–26), pages 128–132, XP004312033 ISSN: 0014–5793 * the whole document * The whole document * The whole document * The supplementary search report has been based on the last set of claims valid and available at the start of the search. Place of search Munich Date of completion of the search Munich 29 July 2005 T: theory or principle underlying the start of the search of the sear	US 5 731 159 A (WALDMAN ET AL) 24 March 1998 (1998-03-24) * the whole document * US 5 601 990 A (WALDMAN ET AL) 11 February 1997 (1997-02-11) * the whole document * DI GUGLIELMO 1 M D ET AL: "Nucleotide requirements for CDX2 binding to the cis promoter element mediating intestine-specific expression of guanylyl cyclase C" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 507, no. 2, 26 October 2001 (2001-10-26), pages 128-132, XP004312033 ISSN: 0014-5793 * the whole document * The whole document * Date of casarch Place of search Munich 29 July 2005 Helliot, B T: theory or principle underlying the invention ender privated in the application current of the same category undolgical background - written disclosure 8: member of the same patent family, corresponding 9: member of the same patent family corresponding 9: member of the same patent

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

29-07-2005

Patent document cited in search report	Publication date		Patent family member(s)		Publication date
US 5518888 A	21-05-1996	AT	259648 1	 [15-03-2004
		AU	681920 E	32	11-09-1997
		ΑU	8124994 <i>F</i>	4	22-05-1995
		CA	2174928 <i>F</i>	A1	04-05-1995
		DE	69433564	01	25-03-2004
		DE	69433564	Γ2	23-12-2004
		EP	0734264	A1	02-10-1996
		ES	2216004	Г3	16-10-2004
		JP	9506340	T	24-06-1997
		NO	961706	A	20-06-1996
		WO	9511694	A1	04-05-1995
		ÜS	6268159 I		31-07-2001
		US	6087109		11-07-2000
		US	5962220		05-10-1999
		US	5879656		09-03-1999
		ÜS	2004029182		12-02-2004
		US	6060037		09-05-2000
US 5731159 A	24-03-1998	US	5601990		11-02-1997
		US	5928873		27-07-1999
		US		A1	10-04-2003
		US		B1	24-09-2002
		ΑT	259648		15-03-2004
		ΑU	681920		11-09-1997
		ΑU	8124994		22-05-1995
		CA	2174928		04-05-1995
		DE		D1	25-03-2004
		DE		T2	23-12-2004
		EP	0734264		02-10-1996
		ES	2216004		16-10-2004
		JP	9506340		24-06-1997
,		NO	961706		20-06-1996
		WO	9511694		04-05-1995
		US	6060037	A 	09-05-2000
US 5601990 A	11-02-1997	AT	259648		15-03-2004
		AU	681920		11-09-1997
		AU	8124994		22-05-1995
		CA	2174928		04-05-1995
		DE	69433564		25-03-2004
		DE	69433564		23-12-2004
		EP	0734264		02-10-1996
		ES	2216004		16-10-2004
		JP	9506340		24-06-1997
045g		NO	961706		20-06-1996
D FORM P0459		US	5928873	Α	27-07-1999
Q					

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 01 92 2785

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

29-07-2005

Patent document cited in search report		Publication date	-	Patent family member(s)		Publication date
US 5601990	A		WO US US US US	9511694 2003068641 6455251 6060037 5731159	A1 B1 A	04-05-1995 10-04-2003 24-09-2002 09-05-2000 24-03-1998
					·	
						÷
FORM P0459						



CLAIMS INCURRING FEES
The present European patent application comprised at the time of filing more than ten claims.
Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
No claims tees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.
LACK OF UNITY OF INVENTION
The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:
see sheet B
All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
1-24 (partially), 33-38 (partially)
None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:

LACK OF UNITY OF INVENTION SHEET B

Application Number

EP 01 92 2785

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1-24, 33-38 (all partially)

An in vitro method of screening an individual for metastatic colorectal cancer cells comprising the steps of examining a sample of extraintestinal tissue and/or body fluid from an individual to determine whether SI is being expressed by cells or whether SI gene transcription or translation product is present in said sample.

An in vitro method for confirming that a tumor cell removed from a patient suspected of having colorectal cancer cells is a colorectal tumor cell, comprising the step of determining whether a tumor cell expresses SI.

A kit for diagnosing an individual who has colorectal

A kit for diagnosing an individual who has colorectal cancer.

A method of treating an individual suspected of suffering from metastasized colorectal cancer comprising the step of administering a therapeutically effective amount of a composition comprising an SI ligand.

A method of radioimaging metastasized colorectal cancer cells comprising the steps of administering to an individual a composition comprising an SI ligand linked to a detectable agent.

2. claims: 1-24 (partially), 25-28 (totally), 34-38 (partially)

An in vitro method of screening an individual for primary and/or metastatic stomach cancer cells comprising the steps of examining a sample of extraintestinal tissue and/or body fluid from an individual to determine whether SI is being expressed by cells or whether SI gene transcription or translation product is present in said sample.

An in vitro method for confirming that a tumor cell removed from a patient suspected of having stomach cancer cells is a stomach tumor cell, comprising the step of determining whether a tumor cell expresses SI.

A method of diagnosing an individual who has stomach cancer comprising the steps of examining a sample of stomach tissue to detect the presence of SI transcript or translation product.

A kit for diagnosing an individual who has stomach cancer. A method of treating an individual suspected of suffering from primary and/or metastatic stomach cancer comprising the step of administering a therapeutically effective amount of a composition comprising an SI ligand.

A method of radioimaging primary and/or metastatic stomach cancer cells comprising the steps of administering to an individual a composition comprising an SI ligand linked to a detectable agent.



LACK OF UNITY OF INVENTION SHEET B

Application Number EP 01 92 2785

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

3. claims: 1-24 (partially), 29-32 (totally), 34-38 (partially)

An in vitro method of screening an individual for primary and/or metastatic esophageal cancer cells comprising the steps of examining a sample of extraintestinal tissue and/or body fluid from an individual to determine whether SI is being expressed by cells or whether SI gene transcription or translation product is present in said sample. An in vitro method for confirming that a tumor cell removed from a patient suspected of having esophageal cancer cells is a esophageal tumor cell, comprising the step of determining whether a tumor cell expresses SI. A method of diagnosing an individual who has esophageal cancer comprising the steps of examining a sample of stomach tissue to detect the presence of SI transcript or translation product.

A kit for diagnosing an individual who has esophageal

A method of treating an individual suspected of suffering from primary and/or metastatic esophageal cancer comprising the step of administering a therapeutically effective amount of a composition comprising an SI ligand.

A method of radioimaging primary and/or metastatic esophageal cancer cells comprising the steps of administering to an individual a composition comprising an SI ligand linked to a detectable agent.

4. claims: 1-24 (all partially)

An in vitro method of screening an individual for metastatic colorectal cancer cells or primary and/or metastatic stomach or esophageal cancer cells comprising the steps of examining a sample of extraintestinal tissue and/or body fluid from an individual to determine whether CDX1 is being expressed by cells or whether CDX1 gene transcription or translation product is present in said sample.

An in vitro method for confirming that a tumor cell removed from a patient suspected of having colorectal, stomach or esophageal cancer cells is a colorectal, stomach or esophageal tumor cell, comprising the step of determining whether a tumor cell expresses CDX1.

5. claims: 1-24 (all partially)



LACK OF UNITY OF INVENTION SHEET B

Application Number

EP 01 92 2785

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

An in vitro method of screening an individual for metastatic colorectal cancer cells or primary and/or metastatic stomach or esophageal cancer cells comprising the steps of examining a sample of extraintestinal tissue and/or body fluid from an individual to determine whether CDX2 is being expressed by cells or whether CDX2 gene transcription or translation product is present in said sample.

An in vitro method for confirming that a tumor cell removed from a patient suspected of having colorectal, stomach or esophageal cancer cells is a colorectal, stomach or esophageal tumor cell, comprising the step of determining whether a tumor cell expresses CDX2.

6. claims: 39-53

A method for identifying a molecular marker useful for detectiong tumor cells metastasized from an origin tissue toa destination tissue or fluid.



专利名称(译)	用于鉴定和靶向癌细胞的组合物和	方法	
公开(公告)号	EP1274861A4	公开(公告)日	2005-09-28
申请号	EP2001922785	申请日	2001-03-27
[标]申请(专利权)人(译)	托马斯杰弗逊大学		
申请(专利权)人(译)	托马斯杰弗逊大学		
当前申请(专利权)人(译)	托马斯杰弗逊大学		
[标]发明人	WALDMAN SCOTT A PARK JASON SCHULZ STEPHANIE		
发明人	WALDMAN, SCOTT, A. PARK, JASON SCHULZ, STEPHANIE		
IPC分类号	G01N33/53 A61K31/196 A61K31/4 /7034 A61K31/704 A61K31/7048 A A61K38/46 A61K39/00 A61K45/00 /04 C12N15/09 C12Q1/02 C12Q1/	A61K31/7068 A61K31/711 A61 A61K47/48 A61K48/00 A61K5	K33/24 A61K38/00 A61K38/43 51/00 A61P1/00 A61P35/00 A61P35
CPC分类号	A61K31/7034 A61K31/7048 A61P- C12Q2600/158 G01N33/57407 G0 /001102 A61K51/1075 C07K16/30	01N33/57419 G01N33/57446 A	
优先权	60/192229 2000-03-27 US		
其他公开文献	EP1274861B1 EP1274861A1		
外部链接	<u>Espacenet</u>		

摘要(译)

公开了用于原发性和/或转移性胃癌或食道癌的筛选和诊断试剂,试剂盒和方法。公开了用于成像和治疗原发性和/或转移性胃癌或食道癌的组合物和方法。公开了用于治疗和预防原发性和/或转移性胃癌或食道癌的疫苗组合物和方法。

Category	Citation of document with in-	dication, where appropriate,	Relevant to claim	CLASSIFICATION OF THE APPLICATION (INLCL7)	
P,X	MAKINO MASATO ET AL of lymph node metast colorectal cancer" ANTICANCER RESEARCH vol. 20, no. 3B, May 2055-2060, XP0080469 ISSN: 0250-7005	f lymph node metastases in invasive early 34-38 olorectal cancer of accept of the control of the			
x	WILTZ O ET AL: "EXI ENZYMATICALLY ACTIVI A UBIQUITOUS PROPER' ADENOCARCINOMAS" GASTROENTEROLOGY, vol. 100, no. 5 PAR' 1266-1278, XP008046 ISSN: 0016-5085	E SUCRASE ISOMALTASE TY OF COLON T 1, 1991, pages	1-20,33		
Υ	* the whole documen	t_*	34-38		
x	LISE M ET AL: "Ass sucrase-1somaltase colorectal cancer." ANNALS OF SURGICAL JOURNAL OF THE SOCI ONCOLOGY. MAR 1997, vol. 4. no. 2. Marc 176-183. XPO0804655 ISSN: 1068-9265 the Whole documen	TECHNICAL FIELDS SEARCHED (InLCI.7)			
x	ZWEIBAUM A ET AL: MARKER OF FETAL AND CELLS OF THE HUMAN INTERNATIONAL JOURN vol. 32, no. 4, 198 XPO08046567 ISSN: 0020-7136 * the whole documen The augmentative against against a page of claim void and asserting	AL OF CANCER, 3, pages 407-412, t_*	E A 21,24		
	Place of search	eron	Examiner		
X:pa Y:pa do A:ba	Munich CATEGORY OF CITED DOCUMENTS iniciately relevant if taken alone infloatery relevant if tombined with ano current of the same category chnological background on-watten disclosure	ther D : document L : document	principle underlying the sient document, but put filing date in cited in the application of the same patent for	n s	